Abstract:Aim: To formulate and assess the anticancer effect of the poly(lactic-co-glycolic acid) (PLGA) copolymer with the thioether groups (diethyl sulfide [Des]) and disulfide bond (cystamine containing disulfide [Cys]), which encapsulated the anticancer drug paclitaxel (PTX) and triggered PTX release in cancer cell H2O2-rich or glutathione-rich surroundings. Methods: PLGA-b-P (Des@Cys) and PLGA-b-P nanoparticles loaded with PTX were prepared and characterized in vitro. The delivery ability of the PLGA-b-P nanoparticles and PLGA-b-P-PTX nanoparticles was assessed on a CT26 (mouse colon cancer cell line) and mouse lung cancer LLC model. Results: The nanoparticles were successfully prepared. Compared with free PTX, the formulated PLGA-b-P nanoparticles loaded with PTX exhibited greater accumulation at the tumor site in the mouse model. Conclusion: PLGA-b-P nanoparticles promote drug accumulation at tumor sites, providing an effective strategy for an intelligent, responsive drug-delivery system. Tweetable abstractThis study prepared polymer nanocarriers (PLGA-b-p-NPs) with double response to the tumor microenvironment and loaded with traditional antitumor drug paclitaxel, so that drugs can accurately reach tumor cells and be rapidly released in cells. Plain language summaryCancer is one of the diseases with the highest mortality rate in the world. Chemotherapy is the most frequently used method of cancer treatment. However, traditional chemotherapeutic drugs have the disadvantages of lack of specificity, high toxicity to the human body, lack of tumor targeting, inability to exist stably in the body, ease of clearance by the body and drug resistance to tumors, so clinical application is limited. Paclitaxel is widely used in the treatment of various cancers, and its use is limited due to the above disadvantages. The purpose of this study was to construct a nanodelivery system with dual responses to the tumor microenvironment, enabling the efficient accumulation of paclitaxel in solid tumors through the enhanced permeability and retention effect, enhancing the therapeutic effect of cancer. This study also investigated the intravenous safety of this dual-responsive nanodelivery system. It evaluated the toxic effects of drug-loaded nanoparticles on cancer cells and validated the controlled release of nanoparticles at tumor sites by in vivo imaging in mice. The authors concluded that tumor microenvironment dual-responsive nanoparticles are a novel and promising nanodelivery system as an intelligently responsive anticancer agent with great promise in future clinical trials.

177Lu-Bombesin-PLGA (paclitaxel): A targeted controlled-release nanomedicine for bimodal therapy of breast cancer

Tumor-Targeting Polycaprolactone Nanoparticles with Codelivery of Paclitaxel and IR780 for Combinational Therapy of Drug-Resistant Ovarian Cancer

Preparation of RGD Peptide/Folate Acid Double-Targeted Mesoporous Silica Nanoparticles and Its Application in Human Breast Cancer MCF-7 Cells

Evaluation of poly (lactic-co-glycolic acid) nanoparticles to improve the therapeutic efficacy of paclitaxel in breast cancer

Development And Evaluation Of A Novel Tpgs-Mediated Paclitaxel-Loaded Plga-Mpeg Nanoparticle For The Treatment Of Ovarian Cancer

mPEG-g-CS-Modified PLGA Nanoparticle Carrier for the Codelivery of Paclitaxel and Epirubicin for Breast Cancer Synergistic Therapy

A Novel Combined Micellar System of Lapatinib and Paclitaxel with Enhanced Antineoplastic Effect Against Human Epidermal Growth Factor Receptor-2 Positive Breast Tumor in Vitro

Facile fabrication of TPGS-PCL polymeric nanoparticles for paclitaxel delivery to breast cancer: investigation of antiproliferation and apoptosis induction

Designing of Polymeric Nanoparticles for Enhanced Breast Cancer Therapy: Combining Paclitaxel, Boric Acid and Tannic Acid for Controlled Drug Delivery

Synthesis and evaluation of a paclitaxel-binding polymeric micelle for efficient breast cancer therapy

Drug-encapsulated blend of PLGA-PEG microspheres: in vitro and in vivo study of the effects of localized/targeted drug delivery on the treatment of triple-negative breast cancer

HPA Aptamer Functionalized Paclitaxel-Loaded PLGA Nanoparticles for Enhanced Anticancer Therapy Through Targeted Effects and Microenvironment Modulation.

Preparation and evaluation of paclitaxel-loaded reactive oxygen species and glutathione redox-responsive poly(lactic-co-glycolic acid) nanoparticles for controlled release in tumor cells

Transcytosable Peptide-Paclitaxel Prodrug Nanoparticle for Targeted Treatment of Triple-Negative Breast Cancer

Paclitaxel-loaded Nanoparticles of Star-Shaped Cholic Acid-Core PLA-TPGS Copolymer for Breast Cancer Treatment.

Enzyme-Sensitive and Amphiphilic PEGylated Dendrimer-Paclitaxel Prodrug-Based Nanoparticles for Enhanced Stability and Anticancer Efficacy

Paclitaxel-loaded and folic acid-modified PLGA nanomedicine with glutathione response for the treatment of lung cancer

Trastuzumab-Coated Nanoparticles Loaded with Docetaxel for Breast Cancer Therapy

Co-Delivery of Gemcitabine and Paclitaxel in cRGD-Modified Long Circulating Nanoparticles with Asymmetric Lipid Layers for Breast Cancer Treatment

Poly-(Lactic-co-Glycolic) Acid Nanoparticles for Synergistic Delivery of Epirubicin and Paclitaxel to Human Lung Cancer Cells

Ginsenoside Rb1 stabilized and paclitaxel / protopanaxadiol co-loaded nanoparticles for synergistic treatment of breast tumor